Biocytogen Pharmaceuticals has announced that its RenMab™ fully human antibody mouse platform has been granted an invention patent by the Japan Patent Office. This achievement marks a significant advancement in the company's global intellectual property strategy, strengthening the patent portfolio for its RenMice® fully human antibody platform. The patent underscores Biocytogen's commitment to innovation and international recognition of its proprietary technologies. The RenMice platform continues to demonstrate strong global competitiveness, with approximately 200 agreements executed for therapeutic antibody co-development and out-licensing as of December 31, 2024.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.